(161 180)eso 1
- a recombinant 19 residue peptide vaccine consisting of amino acids 161 through 180 of the cancer/testis (ct) antigen. Eso 1 (161 180) peptide vaccine may stimulate the host immune system to mount a cytotoxic t lymphocyte (ctl) response against tumor cells positive for eso 1, resulting in decreased tumor growth. Eso 1 is expressed in a variety of cancers, including melanoma, breast, bladder, prostate, and hepatocellular cancers. (nci04)
Up to date info
Latest research - (161 180)eso 1
Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on (161 180)eso 1 for any updates.